Updated on 4 September 2013
Oramed submitted pre-IND to US FDA for its an orally administered exenatide capsule ORMD-0901
Singapore: Oramed Pharmaceuticals, developer of oral drug delivery systems, submitted a pre-investigational new drug (pre-IND) package to the US FDA for ORMD-0901, an orally administered exenatide capsule. Oramed's pre-IND package submission follows its recently announced meeting request letter submitted to the FDA.
The submitted pre-IND package provides the FDA with information on Oramed's ORMD-0901 research conducted to-date, as well as a clinical trial outline for a proposed US clinical trial. The FDA's response to the pre-IND package will serve as a guide to the company for product development and preparation of a full IND application.